188 related articles for article (PubMed ID: 28588061)
1. Dual HER2 Blockade Helps Prevent Breast Cancer Return.
Cancer Discov; 2017 Aug; 7(8):790. PubMed ID: 28588061
[TBL] [Abstract][Full Text] [Related]
2. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
3. FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer.
Howie LJ; Scher NS; Amiri-Kordestani L; Zhang L; King-Kallimanis BL; Choudhry Y; Schroeder J; Goldberg KB; Kluetz PG; Ibrahim A; Sridhara R; Blumenthal GM; Pazdur R; Beaver JA
Clin Cancer Res; 2019 May; 25(10):2949-2955. PubMed ID: 30552112
[TBL] [Abstract][Full Text] [Related]
4. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
5. Pertuzumab and trastuzumab: the rationale way to synergy.
Richard S; Selle F; Lotz JP; Khalil A; Gligorov J; Soares DG
An Acad Bras Cienc; 2016; 88 Suppl 1():565-77. PubMed ID: 27275646
[TBL] [Abstract][Full Text] [Related]
6. [Herceptin monotherapy in HER2(+) recurrent breast carcinoma].
Eidtmann H
Onkologie; 2002 Dec; 25 Suppl 5():14-5. PubMed ID: 23573613
[No Abstract] [Full Text] [Related]
7. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
8. HER2-positive metastatic breast cancer: a changing scenario.
Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
[TBL] [Abstract][Full Text] [Related]
9. Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis.
Zambelli A; Pappagallo G; Marchetti P
J Comp Eff Res; 2020 Apr; 9(6):423-430. PubMed ID: 32057255
[No Abstract] [Full Text] [Related]
10. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.
Gerratana L; Bonotto M; Bozza C; Ongaro E; Fanotto V; Pelizzari G; Puglisi F
Expert Opin Biol Ther; 2017 Mar; 17(3):365-374. PubMed ID: 28092723
[TBL] [Abstract][Full Text] [Related]
11. Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.
Gleeson JP; Keegan NM; Morris PG
Expert Opin Biol Ther; 2018 Mar; 18(3):251-262. PubMed ID: 29183167
[TBL] [Abstract][Full Text] [Related]
12. Pertuzumab: development beyond breast cancer.
Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
[TBL] [Abstract][Full Text] [Related]
13. CLEOPATRA holds strong in final analysis.
Cancer Discov; 2014 Dec; 4(12):OF3. PubMed ID: 25477120
[TBL] [Abstract][Full Text] [Related]
14. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
15. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.
Dawood S; Sirohi B
Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2012 Jul; 54(1395):59-60. PubMed ID: 22825690
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
19. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
Ajgal Z; de Percin S; Diéras V; Pierga JY; Campana F; Fourquet A; Kirova YM
Cancer Radiother; 2017 Apr; 21(2):114-118. PubMed ID: 28347625
[TBL] [Abstract][Full Text] [Related]
20. Dual HER2 blockade slows metastatic breast cancer.
Bender E
Cancer Discov; 2012 Jan; 2(1):OF4. PubMed ID: 22585174
[No Abstract] [Full Text] [Related]
[Next] [New Search]